Analysts Offer Predictions for CervoMed FY2026 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Brookline Capital Markets boosted their FY2026 earnings estimates for shares of CervoMed in a research note issued on Tuesday, November 10th. Brookline Capital Markets analyst F. Ahmed now anticipates that the company will earn ($2.21) per share for the year, up from their prior forecast of ($2.97). The consensus estimate for CervoMed’s current full-year earnings is ($2.23) per share. Brookline Capital Markets also issued estimates for CervoMed’s Q4 2026 earnings at ($0.47) EPS.

CervoMed (NASDAQ:CRVO) last released its earnings results on Monday, November 9th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09.

A number of other analysts have also issued reports on CRVO. Roth Capital set a $7.00 target price on shares of CervoMed in a research note on Thursday, August 20th. Wall Street Zen raised shares of CervoMed from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Chardan Capital upgraded shares of CervoMed to a “strong-buy” rating in a report on Monday, August 3rd. Weiss Ratings cut shares of CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Finally, HC Wainwright restated a “buy” rating on shares of CervoMed in a research note on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $21.00.

CervoMed Stock Performance

CRVO opened at $1.83 on Friday. The business has a fifty day moving average of $2.36 and a 200 day moving average of $3.31. CervoMed has a 52-week low of $1.27 and a 52-week high of $10.00.

Hedge Funds Weigh In On CervoMed

Several institutional investors have recently made changes to their positions in CRVO. NFSG Corp raised its holdings in shares of CervoMed by 283.3% in the third quarter. NFSG Corp now owns 11,500 shares of the company’s stock valued at $34,000 after acquiring an additional 8,500 shares in the last quarter. Citizens Financial Group Inc. RI bought a new position in CervoMed during the 2nd quarter worth about $116,000. Byrne Asset Management LLC increased its position in CervoMed by 248.6% during the 2nd quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock valued at $159,000 after purchasing an additional 36,550 shares during the period. BlackRock Inc. purchased a new position in CervoMed during the 2nd quarter valued at about $167,000. Finally, Renaissance Technologies LLC bought a new stake in shares of CervoMed in the 1st quarter valued at about $252,000. Hedge funds and other institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s lead investigational product is neflamapimod, an orally administered, brain-penetrant small-molecule inhibitor of p38 alpha, an enzyme believed to play a role in neuroinflammation and cognitive decline. CervoMed is primarily evaluating neflamapimod as a potential treatment for dementia with Lewy bodies, a progressive neurological disorder associated with cognitive impairment, fluctuations in attention, visual hallucinations and movement symptoms.